Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography

Janssen, Bieneke; Vugts, Daniëlle J.; Funke, Uta; Molenaar, Ger T.; Kruijer, Perry S.; Berckel, Bart N.M. van; Lammertsma, Adriaan A.; Windhorst, Albert D.

doi:10.1016/j.bbadis.2015.11.011

Cited by 67 publications

(43 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 C-(R)-PK11195 has been the first of those, and in spite of some limitations due to a relatively high level of non-specific binding is still widely used. A large number of second generation tracers with higher specificity has been developed but their binding is subject to a genetic polymorphisms that blurs the advantage of these tracers [454]. Nonetheless, beyond these limitations, the development of these tracers could provide relevant biomarkers and offer new insights in the variability of evolution of AD [455].…”

Section: Contribution and Role Of Positron Emission Tomography (Pet)mentioning

confidence: 99%

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

Hampel

Toschi

Babiloni

et al. 2018

JAD

131

113

View full text Add to dashboard Cite

The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression. This translational research path is paralleled by an “omics”-based, hypothesis-free, exploratory research pathway, which will collect multimodal data from progressing asymptomatic, preclinical and clinical neurodegenerative disease (ND) populations, within the wide continuous biological and clinical spectrum of ND, applying high-throughput and high-content technologies combined with powerful computational and statistical modeling tools, aimed at identifying novel dysfunctional systems and predictive marker signatures associated with ND. The goals are to identify common biological denominators or differentiating classifiers across the continuum of ND during detectable stages of pathophysiological progression, characterize systems-based intermediate endophenotypes, validate multi-modal novel diagnostic systems biomarkers, and advance clinical intervention trial designs by utilizing systems-based intermediate endophenotypes and candidate surrogate markers. Achieving these goals is key to the ultimate development of early and effective individualized treatment of ND, such as Alzheimer’s disease (AD). The Alzheimer Precision Medicine Initiative (APMI) and cohort program (APMI-CP), as well as the Paris based core of the Sorbonne University Clinical Research Group “Alzheimer Precision Medicine” (GRC-APM) were recently launched to facilitate the passageway from conventional clinical diagnostic and drug development towards breakthrough innovation based on the investigation of the comprehensive biological nature of aging individuals. The APMI movement is gaining momentum to systematically apply both systems neurophysiology and systems biology in exploratory translational neuroscience research on ND.

show abstract

Section: Contribution and Role Of Positron Emission Tomography (Pet)mentioning

confidence: 99%

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

Hampel

Toschi

Babiloni

et al. 2018

JAD

131

113

View full text Add to dashboard Cite

show abstract

“…Other targets, such as monoamine oxidase, adenosine receptors, P2X7 receptors or metalloprotease are currently being considered and have been recently and comprehensively reviewed by Janssen et al . (, ).…”

Section: Imaging Biomarkers Of Neuroinflammationmentioning

confidence: 99%

“…Amongst them, the cannabinoid type 2 receptor holds promises, but the first reports using cannabinoid type 2 receptor tracers suggest that both biomarkers and tracers might not be suitable to monitor neuroinflammation in vivo (Vandeputte et al 2012;Ahmad et al 2013). Other targets, such as monoamine oxidase, adenosine receptors, P2X7 receptors or metalloprotease are currently being considered and have been recently and comprehensively reviewed by Janssen et al (2016Janssen et al ( , 2018.…”

Section: Tspo Pet Limitations and Future Biomarkersmentioning

confidence: 99%

In vivo molecular imaging of neuroinflammation in Alzheimer's disease

Chaney

Williams

Boutin

2018

Journal of Neurochemistry

View full text Add to dashboard Cite

It has become increasingly evident that neuroinflammation plays a critical role in the pathophysiology of Alzheimer's disease (AD) and other neurodegenerative disorders. Increased glial cell activation is consistently reported in both rodent models of AD and in AD patients. Moreover, recent genome wide association studies have revealed multiple genes associated with inflammation and immunity are significantly associated with an increased risk of AD development (e.g. TREM2). Non‐invasive in vivo detection and tracking of neuroinflammation is necessary to enhance our understanding of the contribution of neuroinflammation to the initiation and progression of AD. Importantly, accurate methods of quantifying neuroinflammation may aid early diagnosis and serve as an output for therapeutic monitoring and disease management. This review details current in vivo imaging biomarkers of neuroinflammation being explored and summarizes both pre‐clinical and clinical results from molecular imaging studies investigating the role of neuroinflammation in AD, with a focus on positron emission tomography and magnetic resonance spectroscopy (MRS).

show abstract

“…Several studies have shown an inflammatory response in post-mortem tissue samples of AD patients (Cribbs et al, 2012;Sudduth et al, 2013;Gomez-Nicola and Boche, 2015;Janssen et al, 2016;Knezevic and Mizrahi, 2018). Unlike acute inflammation, the anti-inflammatory and pre-inflammatory responses of AD are characterized by chronic inflammation, which occurs when the signal transmission balance is broken (Grammas, 2011;Rubio-Perez and Morillas-Ruiz, 2012;Meraz-Ríos et al, 2013;Ferreira et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Importance of Microglial Cytoskeleton and the Actin-interacting Proteins in Alzheimer's Disease

Choi

2020

BSL

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common neurodegenerative disorder and is expected to become more and more widespread as life expectancy increases. New therapeutic target, as well as the identification of mechanisms responsible for pathology, is urgently needed. Recently, microglial actin cytoskeleton has been proposed as a beneficial role in axon regeneration of brain injury. This review highlights in understanding of the characteristics of microglial actin cytoskeleton and discuss the role of specific actin-interacting proteins and receptors in AD. The precise mechanisms and functional aspects of motility by microglia require further study, and the regulation of microglial actin cytoskeleton might be a potential therapeutic strategy for neurological diseases.

show abstract

Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography

Cited by 67 publications

References 142 publications

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

In vivo molecular imaging of neuroinflammation in Alzheimer's disease

Importance of Microglial Cytoskeleton and the Actin-interacting Proteins in Alzheimer's Disease

Contact Info

Product

Resources

About